Immix Biopharma Stock Market Value
| IMMX Stock | USD 7.33 0.10 1.35% |
| Symbol | Immix |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immix Biopharma. Market participants price Immix higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Immix Biopharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Immix Biopharma's market price often diverges from its book value, the accounting figure shown on Immix's balance sheet. Smart investors calculate Immix Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Immix Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immix Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immix Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immix Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immix Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Immix Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Immix Biopharma.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Immix Biopharma on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Immix Biopharma or generate 0.0% return on investment in Immix Biopharma over 90 days. Immix Biopharma is related to or competes with Coya Therapeutics, Whitehawk Therapeutics, Oncolytics Biotech, Zentalis Pharmaceuticals, Surrozen, Atossa Genetics, and Instil Bio. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therape... More
Immix Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Immix Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Immix Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.29 | |||
| Information Ratio | 0.2195 | |||
| Maximum Drawdown | 28.79 | |||
| Value At Risk | (6.08) | |||
| Potential Upside | 14.88 |
Immix Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immix Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Immix Biopharma's standard deviation. In reality, there are many statistical measures that can use Immix Biopharma historical prices to predict the future Immix Biopharma's volatility.| Risk Adjusted Performance | 0.1949 | |||
| Jensen Alpha | 1.34 | |||
| Total Risk Alpha | 0.9568 | |||
| Sortino Ratio | 0.316 | |||
| Treynor Ratio | 1.08 |
Immix Biopharma February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1949 | |||
| Market Risk Adjusted Performance | 1.09 | |||
| Mean Deviation | 4.82 | |||
| Semi Deviation | 3.74 | |||
| Downside Deviation | 4.29 | |||
| Coefficient Of Variation | 433.3 | |||
| Standard Deviation | 6.18 | |||
| Variance | 38.16 | |||
| Information Ratio | 0.2195 | |||
| Jensen Alpha | 1.34 | |||
| Total Risk Alpha | 0.9568 | |||
| Sortino Ratio | 0.316 | |||
| Treynor Ratio | 1.08 | |||
| Maximum Drawdown | 28.79 | |||
| Value At Risk | (6.08) | |||
| Potential Upside | 14.88 | |||
| Downside Variance | 18.41 | |||
| Semi Variance | 14.02 | |||
| Expected Short fall | (6.29) | |||
| Skewness | 0.705 | |||
| Kurtosis | 0.2504 |
Immix Biopharma Backtested Returns
Immix Biopharma is slightly risky given 3 months investment horizon. Immix Biopharma holds Efficiency (Sharpe) Ratio of 0.2, which attests that the entity had a 0.2 % return per unit of risk over the last 3 months. We have collected data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.14% are justified by taking the suggested risk. Use Immix Biopharma Market Risk Adjusted Performance of 1.09, risk adjusted performance of 0.1949, and Downside Deviation of 4.29 to evaluate company specific risk that cannot be diversified away. Immix Biopharma holds a performance score of 15 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.31, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Immix Biopharma will likely underperform. Use Immix Biopharma maximum drawdown, as well as the relationship between the skewness and day typical price , to analyze future returns on Immix Biopharma.
Auto-correlation | 0.51 |
Modest predictability
Immix Biopharma has modest predictability. Overlapping area represents the amount of predictability between Immix Biopharma time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Immix Biopharma price movement. The serial correlation of 0.51 indicates that about 51.0% of current Immix Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.51 | |
| Spearman Rank Test | 0.55 | |
| Residual Average | 0.0 | |
| Price Variance | 0.68 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.